Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $18

Benzinga · 3d ago
Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $15 to $18.